Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Life insurers' premium income up 19% in Apr-May
Life insurance premiums surged 19% to ₹62,581 crore in April-May, fueled by strong individual policy sales and improved retail demand post-GST exemption. Both LIC and private players saw healthy gains, with overall policy numbers rising 5%. This growth highlights renewed customer interest in savings and protection products.
Ajanta Pharma promoter sells ₹1,024 crore stake; mutual funds step in as buyers
A promoter entity of Ajanta Pharma has sold a 2.8% stake in the drugmaker for over ₹1,000 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund emerging as the key buyers.
Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MF
A promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund acquiring the stake. The transaction comes amid strong earnings growth, healthy margins and sustained momentum in the company’s pharmaceutical business.
Hexagon Nutrition IPO: Issue booked 53 times on Day 3; NII portion sees strong demand, GMP signals healthy listing
Hexagon Nutrition's IPO, which opened from June 5 to June 9, was oversubscribed by over 50 times, with significant participation across all investor categories. The grey market premium suggests a potential listing price of ₹52, reflecting a 15.6% premium over the issue price of ₹45.
Bernstein backs Zydus, Lupin and Sun Pharma on innovation shift
Nandan Kulkarni, Director–India Healthcare & Senior Research Analyst at Bernstein, sees strong opportunities in CDMOs, specialty therapies, biosimilars and licensing deals. While favouring Zydus, Lupin and Sun Pharma, he remains cautious on Biocon and Mankind Pharma, and argues that India's shift from generics to innovation could drive the next phase of growth for the pharma industry.
Capitalmind AMC prefers pharma over banks, sees pressure on consumption sectors
Anoop Vijaykumar, Head of Equities at Capitalmind AMC, says pharma remains one of the most attractive sectors due to healthy earnings growth, reasonable valuations and opportunities in CDMO and generic drug companies. While recent RBI measures could support banks, he prefers mid- and small-cap private lenders over large banks. Vijaykumar is cautious on autos and consumption stocks, warning that elevated oil prices and a weak monsoon could pressure demand and margins in the coming quarters.
Apple expands child safety tools as social media bans grow
Apple is enhancing tools for parents to safeguard children online. New features will allow parents to manage app usage, content access, and communication for their kids. This comes as governments worldwide are restricting social media access for minors. These updates aim to help families establish age-appropriate digital protections and healthy online habits.
Bernstein bets on Indian healthcare, sees these three stocks as key beneficiaries
According to Bernstein, valuations across the Indian biopharma sector have re-rated significantly, with the Nifty Pharma index trading slightly above its 10-year average multiple of 30.5 times its one-year forward earnings. However, it noted that its preferred stocks continue to trade below their long-term average valuations.
Healthy Life Agritec consolidated net profit rises 28.05% in the March 2026 quarter
Sales rise 95.61% to Rs 85.19 crore
Grasim announces ₹3,094-cr investment for lyocell capacity expansion in Karnataka plant
The expansion will add 110,000 TPA capacity at Harihar; total cellulosic staple fibre capacity slated to exceed one million tonnes annually by 2030. Grasim Industries, a Aditya Birla Group company, shares closed at ₹3,060.30 on the NSE on June 8, down 0.89%, or ₹27.40.
Sun Pharma, Alkem Labs, other pharma stocks gain despite stock market crash; Nifty Pharma rises for fourth day in a row - Mint
Sun Pharma, Alkem Labs, other pharma stocks gain despite stock market crash; Nifty Pharma rises for fourth day in a rowMint
Here is the one sector bucking the trend in a weak market; Check out top gainers
Five among the top 10 gainers on the Nifty 500 index are Pharma stocks. They include Pfizer (Up 4.6%), Anthem Biosciences (Up 2.5%), Syngene (Up 2%), Aster DM Healthcare (Up 2%) and Wockhardt (Up 2%).